Anna Pasetto
Overview
Explore the profile of Anna Pasetto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
3229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maravelia P, Yao H, Cai C, Silva D, Fransson J, Nilsson O, et al.
Gut
. 2025 Jan;
PMID: 39832892
Background: Tumour-infiltrating T cells can mediate both antitumour immunity and promote tumour progression by creating an immunosuppressive environment. This dual role is especially relevant in hepatocellular carcinoma (HCC), characterised by...
2.
Mazzotti L, Borges de Souza P, Azzali I, Angeli D, Nanni O, Sambri V, et al.
HLA
. 2025 Jan;
105(1):e70011.
PMID: 39807702
COVID-19 remains a significant global health problem with uncertain long-term consequences for convalescents. We investigated the relationships between anti-N protein antibody levels, severe acute respiratory syndrome (SARS)-CoV-2-associated TCR repertoire parameters,...
3.
Gaimari A, De Lucia A, Nicolini F, Mazzotti L, Maltoni R, Rughi G, et al.
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596267
Recent times have witnessed remarkable progress in cancer immunotherapy, drastically changing the cancer treatment landscape. Among the various immunotherapeutic approaches, adoptive cell therapy (ACT), particularly chimeric antigen receptor (CAR) T...
4.
Chiavelli C, Prapa M, Rovesti G, Silingardi M, Neri G, Pugliese G, et al.
NPJ Precis Oncol
. 2024 Feb;
8(1):26.
PMID: 38302615
Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies. We...
5.
Yan J, Bangalore C, Nikouyan N, Appelberg S, Silva D, Yao H, et al.
Mol Ther
. 2024 Jan;
32(2):540-555.
PMID: 38213030
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific neutralizing antibodies (NAbs) lack cross-reactivity between SARS-CoV species and variants and fail to mediate long-term protection against infection. The maintained protection against severe...
6.
7.
Pasetto A, Buggert M
Methods Mol Biol
. 2022 Sep;
2574:209-219.
PMID: 36087203
T-cell repertoire characterization is a methodology that enables the identification of T-cell receptor (TCR) gene sequences in a T-cell population. TCR genes are composed of modular gene segments V (D)...
8.
Burm R, Maravelia P, Ahlen G, Ciesek S, Caro Perez N, Pasetto A, et al.
Gut
. 2022 Aug;
72(6):1186-1195.
PMID: 35977815
Objective: Chronic HBV/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to...
9.
Mazzotti L, Gaimari A, Bravaccini S, Maltoni R, Cerchione C, Juan M, et al.
Int J Mol Sci
. 2022 Aug;
23(15).
PMID: 35955721
The immune system is a dynamic feature of each individual and a footprint of our unique internal and external exposures. Indeed, the type and level of exposure to physical and...
10.
Kishton R, Patel S, Decker A, Vodnala S, Cam M, Yamamoto T, et al.
Cell Rep
. 2022 Aug;
40(5):111153.
PMID: 35926468
Adoptive T cell therapies (ACT) have been curative for a limited number of cancer patients. The sensitization of cancer cells to T cell killing may expand the benefit of these...